Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis

Apoptosis

Volumn 10, Issue 3, 2005, Pages 583-595

  Gu, G ^a,b   Hentunen, T A ^a   Nars, M ^a   Harkonen P L ^a,c   Vaananen H K ^a,d  

^a UNIVERSITY OF TURKU   (Finland)

^b Drug Discovery Graduate School   (Finland)

^c LUND UNIVERSITY   (Sweden)

^d NONE   (Finland)

Author keywords

Apoptosis; Estrogen; Glucocorticoid; Osteocyte; Osteoporosis

Indexed keywords

DEXAMETHASONE; ESTRADIOL; FULVESTRANT; GLUCOCORTICOID; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; MIFEPRISTONE; PHOSPHATE; PROTEINASE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALVARIA; CELL CULTURE; CELL ISOLATION; CELL NUCLEUS; CELL STRUCTURE; CONTROLLED STUDY; CYTOCHEMISTRY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOCYTE; OSTEOPOROSIS; OSTEOSCLEROSIS; PRIORITY JOURNAL; STAINING; X CHROMOSOME;

ANIMALS; APOPTOSIS; CELL NUCLEUS; CELLS, CULTURED; DEXAMETHASONE; ESTRADIOL; GLUCOCORTICOIDS; IN SITU NICK-END LABELING; MICE; MIFEPRISTONE; OSTEOCYTES; RECEPTORS, GLUCOCORTICOID;

MURINAE;

EID: 21244498229     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10495-005-1893-0     Document Type: Article

References (60)

1. Vaananen KH, Harkonen PL. Bone effects of glucocorticoid therapy. Ernst Schering Res Found Workshop 2002; 40: 55-64.
2. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966: 73-81.
3. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15(6): 993-1000.
4. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326(22): 1473-1479.
5. Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol 2002; 189(12): 1-9.
6. Gustafsson JA, Carlstedt-Duke J, Poellinger L, et al. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev 1987; 8(2): 185-234.
7. Reichardt HM, Tronche F, Berger S, Kellendonk C, Schutz G. New insights into glucocorticoid and mineralocorticoid signaling: Lessons from gene targeting. Adv Pharmacol 2000; 47: 1-21.
8. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab 2000; 85(2): 883-889.
9. Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 2001; 16(8): 1496-1504.
10. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001; 2(1): 65-73.
11. Pereira RM, Delany AM, Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 2001; 28(5): 484-490.
12. Zalavras C, Shah S, Birnbaum MJ, Frenkel B. Role of apoptosis in glucocorticoid-induced osteoporosis and osteonecrosis. Crit Rev Eukaryot Gene Expr 2003; 13(2-4): 221-235.
13. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102(2): 274-282.
14. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85(8): 2907-2912.
15. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104(10): 1363-1374.
16. Jande SS, Belanger LF. The life cycle of the osteocyte. Clin Orthop 1973; 94: 281-305.
17. Jones SJ, Gray C, Sakamaki H, et al. The incidence and size of gap junctions between the bone cells in rat calvaria. Anat Embryol (Berl) 1993; 187(4): 343-352.
18. Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. J Cell Biochem 1994; 55(3): 287-299.
19. Burger EH, Klein-Nulend J. Mechanotransduction in bone - role of the lacuno-canalicular network. Faseb J 1999; 13(Suppl): S101-S112.
20. Lanyon LE. Osteocytes, strain detection, bone modeling and remodeling. Calcif Tissue Int 1993; 53(Suppl 1): S102-S106; discussion S106-S107.
21. Mikuni-Takagaki Y. Mechanical responses and signal transduction pathways in stretched osteocytes. J Bone Miner Metab 1999; 17(1): 57-60.
22. Skerry TM, Bitensky L, Chayen J, Lanyon LE. Early strain-related changes in enzyme activity in osteocytes following bone loading in vivo. J Bone Miner Res 1989; 4(5): 783-788.
23. Ajubi NE, Klein-Nulend J, Alblas MJ, Burger EH, Nijweide PJ. Signal transduction pathways involved in fluid flow-induced PGE2 production by cultured osteocytes. Am J Physiol 1999; 276(1 Pt 1): E171-E178.
24. Cherian PP, Cheng B, Gu S, Sprague E, Bonewald LF, Jiang JX. Effects of mechanical strain on the function of Gap junctions in osteocytes are mediated through the prostaglandin EP2 receptor. J Biol Chem 2003; 278(44): 43146-43156.
25. Klein-Nulend J, Semeins CM, Ajubi NE, Nijweide PJ, Burger EH. Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts - correlation with prostaglandin upregulation. Biochem Biophys Res Commun 1995; 217(2): 640-648.
26. Dodd JS, Raleigh JA, Gross TS. Osteocyte hypoxia: A novel mechanotransduction pathway. Am J Physiol 1999; 277(3 Pt 1): C598-C602.
27. Mason DJ, Suva LJ, Genever PG, et al. Mechanically regulated expression of a neural glutamate transporter in bone: A role for excitatory amino acids as osteotropic agents? Bone 1997; 20(3): 199-205.
28. Huggett JF, Mustafa A, O'Neal L, Mason DJ. The glutamate transporter GLAST-1 (EAAT-1) is expressed in the plasma membrane of osteocytes and is responsive to extracellular glutamate concentration. Biochem Soc Trans 2002; 30(Pt 6): 890-893.
29. Turner CH, Robling AG, Duncan RL, Burr DB. Do bone cells behave like a neuronal network? Calcif Tissue Int 2002; 70(6): 435-442.
30. Heino TJ, Hentunen TA, Vaananen HK. Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: Enhancement by estrogen. J Cell Biochem 2002; 85(1): 185-197.
31. Heino TJ, Hentunen TA, Vaananen HK. Conditioned medium from osteocytes stimulates the proliferation of bone marrow mesenchymal stem cells and their differentiation into osteoblasts. Exp Cell Res 2004; 294(2): 458-468.
32. Noble BS, Stevens H, Loveridge N, Reeve J. Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone 1997; 20(3): 273-282.
33. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14(7): 1061-1066.
34. Wong G, Cohn DV. Separation of parathyroid hormone and calcitonin-sensitive cells from non-responsive bone cells. Nature 1974; 252(5485): 713-715.
35. Hefley TJ. Utilization of FPLC-purified bacterial collagenase for the isolation of cells from bone. J Bone Miner Res 1987; 2(6): 505-516.
36. Spitz IM, Bardin CW. Mifepristone (RU 486)-a modulator of progestin and glucocorticoid action. N Engl J Med 1993; 329(6): 404-412.
37. Sambrook PN, Hughes DR, Nelson AE, Robinson BG, Mason RS. Osteocyte viability with glucocorticoid treatment: Relation to histomorphometry. Ann Rheum Dis 2003; 62(12): 1215-1217.
38. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145(4): 1835-1841.
39. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001; 16(1): 97-103.
40. Eberhardt AW, Yeager-Jones A, Blair HC. Regional trabecular bone matrix degeneration and osteocyte death in femora of glucocorticoid- treated rabbits. Endocrinology 2001; 142(3): 1333-1340.
41. Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 1998; 13(8): 1243-1250.
42. Peck WA, Birge SJ, Jr., Fedak SA. Bone Cells: Biochemical and Biological Studies after Enzymatic Isolation. Science 1964; 146: 1476-1477.
43. Giguere V, Hollenberg SM, Rosenfeld MG, Evans RM. Functional domains of the human glucocorticoid receptor. Cell 1986; 46(5): 645-652.
44. Sanchez ER, Hirst M, Scherrer LC, et al. Hormone-free mouse glucocorticoid receptors overexpressed in Chinese hamster ovary cells are localized to the nucleus and are associated with both hsp70 and hsp90. J Biol Chem 1990; 265(33): 20123-20130.
45. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95(6): 2435-2441.
46. Beato M. Gene regulation by steroid hormones. Cell 1989; 56(3): 335-344.
47. Oakley RH, Sar M, Cidlowski JA. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996; 271(16): 9550-9559.
48. Shoupe D, Mishell DR, Jr., Lahteenmaki P, et al. Effects of the antiprogesterone RU 486 in normal women. I. Single-dose administration in the midluteal phase. Am J Obstet Gynecol 1987; 157(6): 1415-1420.
49. Sasson R, Tajima K, Amsterdam A. Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3′,5′- monophosphate and p53 activation in immortalized human granulosa cells: Involvement of Bcl-2. Endocrinology 2001; 142(2): 802-811.
50. Jenkins BD, Pullen CB, Darimont BD. Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol Metab 2001; 12(3): 122-126.
51. Schmidt M, Lugering N, Lugering A, et al. Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis. J Immunol 2001; 166(2): 1344-1351.
52. Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 1996; 16(1): 59-108.
53. Ahuja SS, Zhao S, Bellido T, Plotkin LI, Jimenez F, Bonewald LF. CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology 2003; 144(5): 1761-1769.
54. Gohel A, McCarthy MB, Gronowicz G. Estrogen prevents glucocorticoid- induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology 1999; 140(11): 5339-5347.
55. Krishnan AV, Swami S, Feldman D. Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 2001; 77(1): 29-37.
56. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138(3): 863-870.
57. Sibonga JD, Dobnig H, Harden RM, Turner RT. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 1998; 139(9): 3736-3742.
58. Turner RT, Evans GL, Dobnig H. The high-affinity estrogen receptor antagonist ICI 182,780 has no effect on bone growth in young male rats. Calcif Tissue Int 2000; 66(6): 461-464.
59. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992; 7(9): 1063-1069.
60. Rhen T, Grissom S, Afshari C, Cidlowski JA. Dexamethasone blocks the rapid biological effects of 17beta-estradiol in the rat uterus without antagonizing its global genomic actions. Faseb J 2003; 17(13): 1849-1870.